Effectiveness of β-lactam and Macrolide Antibiotic Combination in Patients with Community-Acquired Pneumonia: A Review
DOI:
10.29303/jpm.v20i4.8163Published:
2025-06-30Issue:
Vol. 20 No. 4 (2025): Special IssueKeywords:
Antibiotics; CAP; Community Pneumonia; β-lactams; MacrolidesArticles
Downloads
How to Cite
Downloads
Metrics
Abstract
Community-acquired pneumonia (CAP) is a clinically significant lung infection and a leading cause of infectious disease-related death, especially in patients with high-risk factors. This study aims to analyze the effectiveness of a combination of β-lactam and macrolide antibiotics in the treatment of CAP and its impact on reducing mortality. Using the Systematic Literature Review method from sources such as Google Scholar, PubMed, and ScienceDirect, 10 national and international journals were reviewed to evaluate the effectiveness of this combination compared to monotherapy and other combination options. Results showed that the combination of β-lactams and macrolides is effective in improving clinical outcomes, accelerating recovery, and reducing mortality in CAP patients, especially against atypical pathogens that are often not fully treated with β-lactam monotherapy. Factors such as seasonal variations and the patient's state of health also influence the response to this therapy. The most commonly used antibiotics in this combination are Ceftriaxone or Ampicillin/Sulbactam as β-lactams, paired with Azithromycin or Clarithromycin as macrolides. Therefore, the combination of β-lactams and macrolides is considered an effective primary therapy option for CAP, in accordance with the national guidelines for medical services in Indonesia, which allows flexibility in treatment according to the clinical condition of the patient and the characteristics of the pathogen present.
References
A. Torres, C. Cilloniz, R. Niederman, et al., "Pneumonia," Nat. Rev. Dis. Primers, vol. 7, no. 1, p. 59, 2021. doi: 10.1038/s41572-021-00259-0.
N. Y. Farandita, Yulia, and F. Herawati, "Profil penggunaan antibiotik pada pasien pneumonia di komunitas: tinjauan pustaka," Intisari Sains Medis, vol. 13, no. 2, pp. 340–345, 2022.
Kementerian Kesehatan Republik Indonesia, Keputusan Menteri Kesehatan Nomor HK.01.07/MENKES/2147/2023 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Pneumonia. Jakarta: Kemenkes RI, 2023.
Y. Luan, Y. Sun, S. Duan, et al., "Pathogenic bacterial profile and drug resistance analysis of community-acquired pneumonia in older outpatients with fever," J. Int. Med. Res., vol. 46, no. 11, pp. 4596–4604, 2018. doi: 10.1177/0300060518786915.
J. P. Metlay, G. W. Waterer, A. C. Long, et al., "Diagnosis and Treatment of Adults with Community-acquired Pneumonia," Am. J. Respir. Crit. Care Med., vol. 200, no. 7, pp. e45–e67, 2019.
J. A. Ramirez, T. L. Wiemken, P. Peyrani, et al., "Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality," Clin. Infect. Dis., vol. 65, no. 11, pp. 1806–1812, 2017. doi: 10.1093/cid/cix647.
I. Hafni, E. Darmawan, and Akrom, "Evaluasi Terapi Antibiotik pada Pasien Pneumonia Anak Rawat Inap di Rumah Sakit," J. Educ. Dev., vol. 11, no. 1, 2023. doi: 10.37081.
L. Zhu, X. Zhang, J. Liu, et al., "Resistance mechanisms of Streptococcus pneumoniae and Haemophilus influenzae in community-acquired pneumonia," J. Infect. Chemother., vol. 25, no. 4, pp. 283–290, 2019. doi: 10.1016/j.jiac.2019.01.002.
H. Meriyani, D. A. Sanjaya, R. A. Juanita, et al., "Kualitas Penggunaan Antibiotik pada Pasien Community-Acquired Pneumonia di Salah Satu Rumah Sakit di Bali," J. Ilm. Medicamento, vol. 10, no. 1, pp. 35–42, 2024. doi: 10.36733/medicamento.v10i1.7592.
D. M. Musher and A. R. Thorner, "Community-Acquired pneumonia," N. Engl. J. Med., vol. 371, no. 17, pp. 1619–1628, 2014. doi: 10.1056/nejmra1312885.
S. H. Kim, J. H. Kim, J. Y. Lee, et al., "Beta-lactam plus macrolide for patients hospitalized with community-acquired pneumonia: Difference between autumn and spring," J. Korean Med. Sci., vol. 37, p. e324, 2022. doi: 10.3346/jkms.2022.37.e324.
A. Ito, T. Ishida, H. Tachibana, et al., "Usefulness of β-lactam and macrolide combination therapy for treating community-acquired pneumonia patients hospitalized in the intensive care unit," J. Infect. Chemother., vol. 27, no. 10, pp. 1447–1453, 2021. doi: 10.1016/j.jiac.2021.06.003.
V. Salunkhe, "Beta-lactam plus Macrolide vs Fluoroquinolone for Empiric Therapy of Hospitalized Patients with CAP," Univ. Louisville J. Respir. Infections, vol. 3, no. 1, p. 6, 2019. doi: 10.18297/jri/vol3/iss1/6.
W. Nie, B. Li, and Q. Xiu, "β-Lactam/macrolide dual therapy versus β-lactam monotherapy for community-acquired pneumonia," J. Antimicrob. Chemother., vol. 69, no. 6, pp. 1441–1446, 2014. doi: 10.1093/jac/dku033.
R. König, X. Cao, M. Oswald, C. Forstner, et al., "Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? A machine learning approach," Eur. Respir. J., vol. 54, no. 6, p. 1900824, 2019. doi: 10.1183/13993003.00824-2019.
A. Ceccato, C. Cilloniz, I. Martin-Loeches, et al., "Effect of combined β-Lactam/Macrolide therapy on mortality," CHEST, vol. 155, no. 4, pp. 795–804, 2018. doi: 10.1016/j.chest.2018.11.006.
J. Suzuki, Y. Sasabuchi, S. Hatakeyama, et al., "Azithromycin plus β-lactam versus levofloxacin plus β-lactam," J. Infect. Chemother., vol. 25, no. 12, pp. 1012–1018, 2019. doi: 10.1016/j.jiac.2019.05.027.
T. T. Gilbert, R. J. Arfstrom, S. W. Mihalovic, et al., "Effect of β-Lactam plus macrolide vs fluoroquinolone on 30-Day readmissions," Am. J. Ther., vol. 27, no. 2, pp. e177–e182, 2018. doi: 10.1097/mjt.0000000000000788.
J. Y. Lee, S. H. Shin, Y. Kim, et al., "Clinical outcomes of beta-lactam plus macrolide versus beta-lactam monotherapy for pneumonia," J. Clin. Pharm. Ther., vol. 42, no. 4, pp. 495–501, 2017. doi: 10.1111/jcpt.12531.
D. Prakoso, P. Jimmy, and N. Edward, "Gambaran dan Rasionalitas Penggunaan Antibiotik pada Pasien Dewasa dengan CAP," J. e-Biomedik, vol. 6, no. 2, 2018.
J. Okumura, Y. Shindo, K. Takahashi, et al., "Mortality in patients with community-onset pneumonia at low risk of drug-resistant pathogens," Respirology, vol. 23, no. 5, pp. 526–534, 2017. doi: 10.1111/resp.13232.
Y. S. Kwon, Y. J. Park, H. C. Park, et al., "Interactions between beta-lactam antibiotics and other drugs: A systematic review and practical recommendations," J. Clin. Pharm. Ther., vol. 47, no. 5, pp. 818–828, 2022. doi: 10.1111/jcpt.13495.
R. Rahardjoputro, Ernawati, and N. R. Widyaningrum, "Efektivitas Antibiotik Empiris untuk Pasien Pneumonia Komunitas Dewasa di RS X Surakarta," SEN TRI: Jurnal Riset Ilmiah, vol. 3, no. 2, pp. 687–694, 2024.
F. Herawati and R. Yulia, "Kajian Literatur: Efektivitas Antibiotik Golongan Beta-Laktam pada Pasien Lansia dengan Pneumonia Komunitas," J. Sains Farmasi & Klinis, vol. 8, no. 2, pp. 81–91, 2021.
S. Rike, "Comparison between Monotherapy and Combination Therapy among Patients with Community-Acquired Pneumonia," J. Ilm. Farmasi, vol. 17, no. 1, pp. 56–63, 2021.
H. Sitong, et al., "Peralihan Antibiotik Intravena ke Oral terhadap Lama Rawat Inap Pasien Pneumonia Komunitas," Pharmacy: J. Farmasi Indonesia, vol. 18, no. 2, pp. 248–256, 2019.
B. B. Haris, et al., "Perbandingan Efikasi Klinis Terapi Antibiotik pada Pasien Pneumonia Komunitas di RSUD Provinsi NTB," J. Ilm. Univ. Mataram, vol. 2, no. 1, pp. 1–10, 2021.
L. Sulaiman and F. Rahmawati, "Penggunaan Obat Antibiotik pada Pasien Pneumonia di Rumah Sakit," Makassar Pharm. Student J., vol. 3, no. 1, pp. 201–210, 2021.
Ministry of Health of the Republic of Indonesia, Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/659/2017 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Pneumonia, Jakarta: Kemenkes RI, 2017.
Perhimpunan Dokter Paru Indonesia, Pneumonia Komunitas. Dalam: Pedoman Diagnosis dan Penatalaksanaan di Indonesia, 2022.
C. Lior, et al., "Profil Penggunaan Antibiotik pada Pasien Pneumonia di Komunitas," Intisari Sains Medis, vol. 10, no. 2, pp. 1312–1320, 2019.
D. F. Postma, et al., "Antibiotic Treatment Strategies for Community-Acquired Pneumonia in Adults," N. Engl. J. Med., vol. 372, no. 14, pp. 1312–1323, 2015.
T. Tejaswini, et al., "Comparative Study of Efficacy and Safety of Levofloxacin and Ceftriaxone in Community-Acquired Pneumonia," J. Clin. Diagn. Res., vol. 12, no. 8, pp. 1–5, 2018.
Anonymous, Pedoman Penggunaan Antibiotik di Rumah Sakit. Geneva: World Health Organization, 2015.
U. Frank, et al., "Comparative Efficacy and Safety of Moxifloxacin and Levofloxacin in the Treatment of Community-Acquired Pneumonia: A Meta-Analysis," J. Chemother., vol. 28, no. 2, pp. 95–105, 2016.
N. Garin, et al., "β-Lactam Monotherapy vs β-Lactam–Macrolide Combination Treatment in Moderately Severe Community-Acquired Pneumonia," JAMA Intern. Med., vol. 174, no. 12, pp. 1894–1901, 2014.
G. Tiseo, G. Grassi, G. M. Rossolini, et al., "Macrolide-based combination therapy in community-acquired pneumonia: A meta-analysis of 47 studies," J. Clin. Virol., vol. 164, p. 105519, 2023. doi: 10.1016/j.jcv.2023.105519.
E. J. Giamarellos-Bourboulis, M. Tsilika, C. Routsi, et al., "Clarithromycin as adjunct therapy in severe community-acquired pneumonia: the ACCESS randomised trial," Lancet Respir. Med., vol. 11, no. 3, pp. 234–244, 2023. doi: 10.1016/S2213-2600(23)00412-5.
H. Shoji, M. Mizunuma, H. Okamoto, et al., "Combination therapy with macrolides reduces mortality in critically ill patients with severe community-acquired pneumonia," BMC Infect. Dis., vol. 21, p. 611, 2021. doi: 10.1186/s12879-021-06317-6.
L. Weng, H. Xu, Q. Cheng, et al., "Effectiveness of β-lactam plus macrolide combination vs monotherapy for adult patients with community-acquired pneumonia: A meta-analysis of RCTs," Antibiotics, vol. 13, no. 2, p. 141, 2024. doi: 10.3390/antibiotics13020141.
Author Biographies
Nurul Hikmah, Department of Pharmacy, Faculty of Health Sciences, Universitas Singaperbangsa Karawang
Mally Ghinan Sholih, Department of Pharmacy, Faculty of Health Sciences, Universitas Singaperbangsa Karawang
License
Copyright (c) 2025 Nurul Hikmah, Mally Ghinan Sholih
This work is licensed under a Creative Commons Attribution 4.0 International License.
The following terms apply to authors who publish in this journal:
1. Authors retain copyright and grant the journal first publication rights, with the work simultaneously licensed under a Creative Commons Attribution License 4.0 International License (CC-BY License) that allows others to share the work with an acknowledgment of the work's authorship and first publication in this journal.
2. Authors may enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., posting it to an institutional repository or publishing it in a book), acknowledging its initial publication in this journal.
3. Before and during the submission process, authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website), as this can lead to productive exchanges as well as earlier and greater citation of published work (See The Effect of Open Access).
